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Abstract Viral agents have been suspected as participants of
immune-mediated disorders. In the case of rheumatic diseases,
the synovial joint cavity represents a secluded area of inflam-
mation which could harbor etiological agents. We analyzed by
polymerase chain reaction the possible presence of DNA from
various herpes viruses in blood and synovial fluid from patients
with either rheumatoid arthritis (n=18), axial spondyloarthritis
(n=11), or osteoarthritis (n=8). Relevant findings were as fol-
lows: DNA from varicella zoster virus was found in synovial
fluid but not in blood mononuclear cells from 33 % of patients
with rheumatoid arthritis and in 45 % of patients with axial
spondyloarthritis but not in patients with osteoarthritis. Also,
DNA from herpes simplex viruses 1 and 2 was found both in
the blood and in the synovial fluid from 33 % of patients with
rheumatoid arthritis. Our results indicate the occasional pres-
ence of DNA from herpes viruses in patients with rheumatoid
arthritis or with axial spondyloarthritis. However, these find-
ings might represent a parallel epiphenomenon of viral activa-
tion associated either with immunosuppressive therapy or with
primary immune disturbances, rather than the etiological par-
ticipation of herpes viruses in these disorders.
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Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease of
the synovium and other tissues; its origin is unknown but its
immunopathology includes T cell and B cell abnormalities
leading to autoimmunity. The cause of RA has been linked to
the interaction of genetic susceptibility and environmental fac-
tors; infectious agents have long been suspected but no defin-
itive data on the role of viral infections has been demonstrated
[1–3]. Epstein-Barr virus (EBV), human herpes virus 6
(HHV6), and human parvovirus B19 have been weakly impli-
cated in RA [4–10]; a recent study found no DNA from herpes
simplex viruses 1 and 2 (HSV1-2) or varicella zoster virus
(VZV) in peripheral blood cells and urine from RA patients
[1, 11]; the possible participation of measles virus has also been
suggested [12]. A meta-analysis on the relation between meth-
otrexate and viral infections in patients with RA did not show
any significant association with VZV, whereas the association
with HS was low [13]. However, the advent of novel immuno-
suppressive agents for the treatment of RA has also increased
the risk of associated viral or bacterial infections. An increased
risk of zoster in RA patients has been found [1, 3], particularly
in subjects older than 60 years and those under novel immuno-
suppressive treatment regimens [1], specifically, TNF antago-
nists like adalimumab, infliximab, and etanercept [3]. Similar
risks for other herpes viruses have been described in patients
under selective immunosuppressive therapy [13, 14].
A study on the synovial fluid and synovial membrane from
patients with several rheumatic diseases using polymerase
chain reaction (PCR) analysis was demonstrated in few cases
of DNA from different viruses, including cytomegalovirus, par-
vovirus B1, Epstein-Barr virus, and herpes simplex; however,
adenovirus or VZV were not found [15]. Thus far, an associa-
tion between viral infections and axial spondyloarthritis (ASA)
has not been reported.
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In multiple sclerosis (MS), another immune-mediated disor-
der, we have reported an association with VZV, including the
finding of VZV in cerebrospinal fluid and in mononuclear cells
fromMS patients during active relapses of the disease [16]; RA
and MS share genetic factors such as the DRB1*04 allele
known to participate in both diseases, RA and MS [17, 18].
In this study, we aimed to identify DNA from various her-
pes viruses (VZV, HSV1 and 2, EBV, and HHV6) in the sy-
novial fluid (SF) and peripheral blood mononuclear cells




A cross-sectional study was made with 15 adult patients with
RA and 11 adult patients with ASA including cases with pe-
ripheral joint involvement, as well as in 8 patients with OA
requiring synovial fluid drainage of at least one knee for ther-
apeutic purposes. Patients were not included in the study if
they had any previous trauma as cause of knee swelling or if
they had been subjected to synovial fluid aspiration with or
without glucocorticoid intra-articular injection in the last
3 months. In addition, patients having any symptom sugges-
tive of infectious disease within the last week were not includ-
ed. We also recorded demographic, therapeutic, and clinical
data (Table 1). The institutional review board at each center
approved the study’s protocol; patients agreed to participate in
the study by signing an informed consent form.
Clinical samples
Four milliliters of peripheral blood were treated with 0.02 ml
of ethylenediaminetetraacetic acid (EDTA); PBMC were
separated by gradient centrifugation with Ficoll, and DNA
was extracted with a kit Qiagen and precipitated with
isopropanol. Also, 0.3 ml of SF were treated with 400 μl
digestion buffer (500 mM tris, pH 9; 20 mM EDTA, 10 mM
NaCl, 1 % sodium dodecyl sulfate, 0.5 mg/ml de proteinase
K) for 18 h at 60 °C. Afterwards, proteins were precipitated
with 100 μl of protein precipitation solution (Qiagen). DNA
was precipitated with isopropanol, dried at room temperature,
and dissolved in 100 μl of sterile water. No patient had previ-
ous history of herpes zoster.
Determination of DNA from VZV, EBV, and HHV6
The absolute quantification of viral load was made by real-
time PCR. The primers and probes (Table 2) were derived
from VZV, strain ORF 31 (gene gB), Epstein-Barr virus (gene
gp85), and human herpes virus 6 (gene U29), and designed
using Primer Express Software (Ver. 2.0); they were synthe-
sized by Applied Biosystems (Mexico). The TaqMan probes
were purchased from Applied Biosystems (Mexico). Each
25 μl of PCR mixture contained 100 ng of DNA either from
blood mononuclear cells or from SF in 5 μl of distilled water,
plus 12.5 μl of TaqMan universal PCR master mix (Applied
Biosystems) and 1.25 μl of primer mixture with a final con-
centration of each primer of 0.9 μM and of each probe se-
quence of 0.25 μM. The TaqMan RNAse P was performed to
normalize each sample. In addition, reactionmixtures contain-
ing the appropriate probe and primer system but without DNA
were run on all plates by triplicate and used as negative con-
trols. The PCR mixtures in 96-well microtiter plates were first
incubated at 95 °C for 10 min, followed by 50 two-step cycles
at 95 °C for 10 s and at 60 °C for 1 min, using an ABI PRISM
7500 real-time PCR system (Applied Biosystems). For each
reaction, real-time fluorescence values were measured as a
function of the quantity of a reporter dye (6-carboxy-fluores-
cein [FAM]) released during amplifications. A threshold cycle
Table 1 Demographic and
clinical features of the population







Male 3 (18) 7 (64) 4 (50)
Female 12 (82) 4 (36) 4 (50)
Age, years, mean 43±12 36±9 60±8
Disease duration, years, mean 8±6 12±7 12±10
DAS 28 ESR, mean 4.2 (1.0) – –
BASDAI, mean – 3.7 (2.4) –
Methotrexate 11 (73) 1 (9) 0
Leflunomide 2 (18) 0 0
Sulfasalazine 7 (47) 6 (55) 0
Hydroxychloroquine 2 (18) 0 0
Prednisone 8 (17) 1 (9) 0
Number in parenthesis represent percentages
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(Ct) value for each sample was determined as the number of
the first cycle at which the measured fluorescence exceeded
the threshold limit (10 times the standard deviation of the
baseline). Ct values observed for DNA samples were used to
calculate the VZV concentration based on the standard curve
for the plasmid-containing test sequence.
Determination of DNA from HSV1 and 2
The absolute quantification of HSV1-2 viral load was made
by real-time PCR using HSV1 and 2 real-time PCR kit
(Shanghai ZJ Bio-Tech Co.) according to the manufacturing
specifications which included the sequences of the primers
used. Briefly, a standard curve was generated by serial dilu-
tions from 1×107 copies/ml to 1×104 copies/ml. Each 40-μl
PCR mixture contained 100 ng of DNA either from blood
mononuclear cells or from SF in 4 μl of distilled water, plus
35 μl of reaction mix (Shanghai ZJ Bio-Tech Co.) and 0.4 μl
of enzyme mix with 0.1 μl of internal control. In addition,
reaction mixtures containing the appropriate reaction mix
but without DNAwere run on all plates by triplicate and used
as a negative control. The PCR mixtures in 96-well microtiter
plates were first incubated at 37 °C for 2 min, one cycle; 94 °C
for 2 min, one cycle; 93 °C for 15 s and 60 °C for 60 s,
40 cycles, using an ABI PRISM 7500 real-time PCR system
(Applied Biosystems). For each reaction, real-time fluores-
cence values were measured as a function of the quantity of
a reporter dye (6-FAM) released during amplifications. A Ct
value for each sample was determined as the number of the
first cycle at which the measured fluorescence exceeded the
threshold limit (10 times the standard deviation of the base-
line). Ct values observed for DNA standards were used to
calculate the HSV1 and 2 amount based on the standard curve
for the positive control included in the kit.
IgG and IgM antibodies against HSV in SF and in serum
Additionally, after the results of PCR were obtained, the se-
rum and SF were studied for IgG and IgM antibodies to HSV
1. The Enzygnost Anti-HSV1 assays for the detection of HSV-
specific IgG and IgM (DiaSorin) were made by the enzyme-
linked immunosorbent assay (ELISA) test as follows: Serum
samples and SF were diluted 1:100. Samples and controls of
100 μl (negative, positive, and cut-off) were added to each
well and incubated for 1 h at 37 °C. After incubation, the plate
was washed with wash buffer; 100 μl working enzyme tracer
was added to each well and incubated for 1 h at 37 °C. After-
wards, the plate was washed with a wash buffer. Chromogen/
substrate of 100 μl was added and incubated for 30 min at
room temperature, in the dark. Finally, 200 μl stop solution
was added and the plate was read as absorbance values at 450/
630 nm using a Labsystems Uniskan II plate reader. Samples
with absorbance values greater than or equal to the cut-off
value were considered positive and negative when the values
were less than the cut-off value.
Results
We studied 15 patients with RA, 11 with ASA, and 8 with OA.
Mean disease duration was 8±6 years in patients with RA, 12
±7 years in those with ASA, and 12±10 years in those with
OA. Demographic and clinical data is shown in Table 1. Most
patients with RA were on treatment with disease-modifying
antirheumatic drugs (DMARD), methotrexate, sulfasalazine,
and prednisone; two on leflunomide; and two on
hydroxychloroquine. Six patients with ASA received
sulfasalazine, one methotrexate, and one prednisone. Regard-
ing biologic therapy, one patient with RAwas receiving ritux-
imab and two with ASAwere receiving infliximab.
Two relevant findings emerged from the molecular analysis
in search for herpes viruses in PBMC and in SF (Table 3): (1)
VZV DNA was found in the SF of a significant number of
patients either with RA (33 %) or with ASA (45 %); however,
VZV DNAwas not found in the PBMC in any case. In con-
trast, VZV was absent in both PBMC and SF from patients
with OA. (2) DNA from HSV1-2 was found in PBMC from 5
(33%) patients as well as in the SF from 5 (33%) patients with
RA; these viruses were not detected in PBMC or SF from
patients either with ASA or with OA (Tables 3 and 4).
In the analysis of HSV1-2, a coincidence of positive find-
ings both in PBMC and in SF from RA patients was ob-
served in four out of five positive cases (cases 5, 6, 7, and
8). Also, a high load of viral DNA from HSV1-2 was ob-
served in two patients with RA (cases 6 and 7) as compared
with the other positive cases, who had a far lower viral load
(cases 4, 5, 8, and 15) (Table 3). Analysis of antibodies (IgG
and IgM) against HSV did not show correlative results in
serum and SF, nor among positive and negative cases in the
PCR analysis; results were positive in about 50 % of all
Table 2 Oligonucleotide primers
Viral target Gene Forward primer Reverse primer TaqMan probe Product size (pb)
VZV ORF-31 5′-CACAAAAACACCCGACTCGAA-3′ 5′-AAT GGC ACG AAC TCA ACT G-3′ 1299 T 65
EBV gp85 5′-TCCGGCAGGTCCTTCGT-3′ 5′-CGAGTGACCGAGAAGGGAGAT-3′ 1523 T 67
HHV6 U29 5′-TTGTCTGTTGTCATGCGTCA-3 5′-TCCCATACTGGAGCTTTGCT-3′ 713 T 181
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Table 3 RT/PCR in PBMC and synovial fluid for herpes viruses
Case no. Diagnosis PBMC Synovial fluid
VZV (# copies) HSV1/HSV2 (# copies) EBV HHV6 VZV (# copies) HSV1/HSV2 (# copies) EBV HHV6
1 RA 0 0 − − 0 0 + −
2 RA 0 0 + − 772 0 − −
3 RA 0 0 − − 1005 0 + −
4 RA 0 137 + − 0 0 − −
5 RA 0 556 + − 116 80 + −
6 RA 0 1,400,567 − − 0 6344 + −
7 RA 0 710,228 + − 0 854,725 + −
8 RA 0 479 + − 0 641 − −
9 RA 0 0 + − 0 0 − −
10 RA 0 0 − − 0 0 − −
11 RA 0 0 + − 189 0 + −
12 RA 0 0 − − 0 0 + −
13 RA 0 0 − − 0 0 − −
14 RA 0 0 − − 0 0 − −
15 RA 0 0 − − 1441 936 − −
16 ASA 0 0 + − 2313 0 + −
17 ASA 0 0 − − 0 0 − −
18 ASA 0 0 − − 1516 0 − −
19 ASA 0 0 − − 2252 0 − −
20 ASA 0 0 − − 0 0 + −
21 ASA 0 0 − − 0 0 − −
22 ASA 0 0 − − 0 0 − −
23 ASA 0 0 − − 140 0 + −
24 ASA 0 0 − − 0 0 − −
25 ASA 0 0 − − 0 0 − −
26 ASA 0 0 + − 187 0 − −
27 OA 0 0 − − 0 0 + −
28 OA 0 0 + − 0 0 − −
29 OA 0 0 + − 0 0 − −
30 OA 0 0 − − 0 0 − −
31 OA 0 0 − − 0 0 − −
32 OA 0 0 − − 0 0 − −
33 OA 0 0 − − 0 0 − −
34 OA 0 0 − − 0 0 − −
Table 4 DNA from herpes viruses in PBMC and synovial fluid from patients with rheumatoid arthritis, axial spondyloarthritis, or osteoarthritis
Diagnosis PBMC Synovial fluid
VZV+ (%) HSV1/HSV2+ (%) EBV+ (%) HHV6+ (%) VZV+ (%) HSV1/HSV2+ (%) EBV+ (%) HHV6+ (%)
RA (n=15) 0 5 (33) 7 (47) 0 5 (33) 5 (33) 7 (47) 0
ASA (n=11) 0 0 2 (18) 0 5 (45) 0 3 (27) 0
OA (n=8) 0 0 2 (25) 0 0 0 1 (13) 0
Total (n=34) 0 5 (15) 11 (32) 0 10 (29) 5 (15) 11 (32) 0
RA rheumatoid arthritis, ASA axial spondyloarthritis, OA osteoarthritis, PBMC peripheral blood mononuclear cells
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samples, regardless on the group source of the specimen
(results not shown).
Positive results for DNA from EBV in both PBMC and SF
were frequent in patients from all three groups, although the
percentage was higher but statistically non-significant for RA
patients (47 % in PBMC and 47 % in SF) than for ASA (18
and 27 %) or OA patients (25 and 13 %). Also, a high con-
cordance was observed between positive samples for EBV in
PBMC and in SF (Table 4). The findings of positive cases for
EBV in PBMC were similar to those found by us in healthy
controls in previous studies [16].
Discussion
Our study discloses some intriguing features in regard to the
potential participation of herpes viruses in RA and ASA.
First, the conspicuous participation of a herpes virus in any
of the three disorders studied was not observed (RA, ASA, or
OA). Nonetheless, herpes simplex virus was found in one
third of RA cases; the simultaneous presence of DNA from
HSV1-2 in blood and in synovial joint cavity of most positive
cases (four out of five) indicates a possible association of
HSV with the immunological disturbances of some patients
with RA; nevertheless, the relatively low frequency of posi-
tive cases does not support the idea of an etiological link. The
finding of viral DNA in the SF of the actively inflamed joint
might have two explanations, either the viral DNA was pas-
sively carried by leucocytes migrating from the blood to the
SF or HSV was in actual replication within the synovial
membrane as an epiphenomenon related with the systemic
immune disturbances associated to RA. Less probable would
be a direct etiological link of HSV1-2 infection as a trigger
for the immune-related pathophysiology of RA; the most rel-
evant argument against this speculation is the absence of the-
se viruses in two thirds of RA cases studied. Currently, we are
searching by ultrastructural studies the possible presence of
viral particles in the SF of positive cases for PCR analysis,
which would indicate an actual local replication of viruses,
rather than the passive carriage of viral DNA by blood leu-
kocytes to the synovial space. It is noteworthy that the
amount of HSV copies was rather high in PBMC and SF
from two patients with RA (cases 6 and 7, Table 3); however,
the absence of these viruses in other similar cases precludes
the speculation of a potential etiological participation.
Also difficult to explain is the finding of VZV DNA in the
synovial joint cavity in about one third of patients either with
RA or with ASA, whereas no viral DNA was found in the
PBMC from the same patients. In another immune-mediated
disorder, multiple sclerosis (MS), we have demonstrated a
high content of VZV DNA and viral particles within the ce-
rebrospinal fluid, which, similarly with the synovial space in
RA, the subarachnoid space in MS represents a secluded area
related with the pathophysiology of the disease [16]. The find-
ing of VZV in a high percentage of MS cases was restricted to
the relapse period of disease. However, in comparison with
MS cases, in RA patients, the finding of VZV DNA was in-
frequent even when all clinical samples from RA patients
included in this study were taken during periods of inflam-
matory activity. Additionally, in the case of RA and ASA,
the absence of VZV DNA in two thirds of cases, and the
absence of VZV DNA in the PBMC from those cases that
were positive in SF, as well as the relatively low number of
viral copies found within the synovial space makes remote
the possibility of a potential causal association of VZVeither
with RA or with ASA. Nevertheless, the sporadic demon-
stration of VZV DNA within the synovial joint cavity might
also indicate a possible epiphenomenon of viral replication
associated either with the primary immune disturbances of
these disorders or with the immune depression produced by
therapeutic drugs, which are commonly administered to pa-
tients with RA or with ASA. In support of this potential
explanation is relevant to point out that the three patients
receiving biologic therapy, either rituximab, or infliximab
(cases 3 RA, 16 ASA, and 18 ASA; Table 3) were positive
for VZV DNA in the synovial fluid.
Although an increased risk for zoster has been reported
in RA patients, this feature has been noted mostly in older
subjects and in patients under immunosuppressive therapy
[1, 3, 19, 20]. However, the inverse relation of the risk for
RA or ASA in subjects with VZV infections has not been
studied, aside from anecdotal reports of cases of transient
and ephemeral arthritis at the time of VZV infection or a
case of RA remission simultaneous with a disseminated
zoster infection [21, 22].
We conclude that HSV1-2 and VZVare occasionally pres-
ent in patients with RA; VZV is also occasionally present in
patients with ASA. No DNA from herpes viruses were found
in patients with OA. Although our results do not support the
idea of an etiological link between RA or ASA and herpes
viruses, a small group of these patients show the actual pres-
ence of DNA from these viruses concordant with the inflam-
matory activity of RA and ASA.
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